Streetbeat News

Products Services

SAM

Boston Beer (SAM) is trading above its 50 and 200-day SMAs, indicating potential growth. The company is focusing on brand revival, cost-saving, and innovation, but faces challenges with its Truly Seltzer brand.

Portfolio Pulse from

December 09, 2024 | 5:30 pm

HSAI

Hesai Technology (HSAI) will supply 1.5 million lidar units to Changan Automobile for its new intelligent driving platform, becoming the exclusive supplier for multiple car models.

Portfolio Pulse from

December 09, 2024 | 5:30 pm

BKTI

BK Technologies is poised for significant growth with its BKR-9000 radios and InteropONE software, targeting higher margins and a 30% sales increase by 2025.

Portfolio Pulse from

December 09, 2024 | 5:30 pm

AME

FTV

ITRI

The Zacks Electronics - Testing Equipment industry is experiencing growth due to strong demand for testing instruments and the potential of 5G technology. Companies like Fortive Corporation (FTV), Ametek, Inc. (AME), and Itron, Inc. (ITRI) are well-positioned to benefit from these trends.

Portfolio Pulse from

December 09, 2024 | 5:30 pm

CRWD

Adaptive Shield, a subsidiary of CrowdStrike, has been recognized as the leader in the 2024 Frost Radar for SaaS Security Posture Management, highlighting its market leadership in securing SaaS applications.

Portfolio Pulse from

December 09, 2024 | 5:30 pm

APTO

Aptose Biosciences presented clinical data at the 2024 ASH Annual Meeting, highlighting the efficacy of their lead compound tuspetinib in combination therapies for AML. The TUS+VEN+AZA triplet therapy is being tested for newly diagnosed AML patients, showing promise in overcoming VEN resistance and being well-tolerated.

Portfolio Pulse from

December 09, 2024 | 5:15 pm

IRON

Disc Medicine presented positive clinical and translational data at the ASH 2024 meeting, highlighting advancements in their hematologic disease treatments, including bitopertin and DISC-3405.

Portfolio Pulse from

December 09, 2024 | 5:15 pm

UPST

Upstart, an AI lending platform, is expanding into new markets with its innovative products, which could positively impact its stock.

Portfolio Pulse from

December 09, 2024 | 5:15 pm

RIGL

Rigel Pharmaceuticals announced initial data from its Phase 1b study of R289 in LR-MDS patients, showing promising results with 40% response in certain patients. The drug was well tolerated, indicating potential for further development.

Portfolio Pulse from

December 09, 2024 | 5:15 pm

AKTS

RFIL

The accelerated deployment of 5G is boosting the prospects of the Zacks Semiconductors - Radio Frequency industry, benefiting companies like RF Industries and Akoustis Technologies despite challenging macroeconomic conditions.

Portfolio Pulse from

December 09, 2024 | 5:15 pm